Trial Profile
Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 26 Mar 2020
Price :
$35
*
At a glance
- Drugs Plecanatide (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Synergy Pharmaceuticals Inc
- 17 Mar 2020 Primary endpoint (Overall Responder 9/12 Weeks (1.0 mg Plecanatide)) has not been met as per Results published in the Digestive Diseases and Sciences
- 17 Mar 2020 Primary endpoint (Overall Responder 9/12 Weeks 0.3 and 3.0 mg plecanatides) has been met as per Results published in the Digestive Diseases and Sciences
- 17 Mar 2020 Results published in the Digestive Diseases and Sciences